Description

Pfizer’s independent medical education initiative supports programs that strengthen healthcare professionals’ competence, clinical confidence, and multidisciplinary coordination in using BCMA-directed bispecific antibodies (BsAbs) for second-line and later (2L+) relapsed/refractory multiple myeloma (RRMM). Education should translate emerging evidence into practice, including interpretation of study designs, patient populations, endpoints, follow-up duration, and limitations.

Priorities include addressing implementation gaps in community oncology, preparing teams for earlier-line BCMA BsAb use, coordinating care, and navigating patient selection and treatment sequencing. The target audience includes hematologists/oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other professionals caring for people with RRMM. Supported formats include case-based learning, workshops, tumor boards, society programs, online courses, webinars, downloadable tools, articles, social media content, videos, podcasts, infographics, and animations.